Adding topiramate to valproic acid.
- Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
- Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
- Start topiramate according to general dosing advice. Pharmacologic response to the drugs should be monitored more closely following addition or withdrawal of one or the other drug. 
- Topiramate has been shown to produce a small but significant increase in valproate clearance, reducing plasma levels.
- Topiramate plasma levels are increased by about 15% by valproate, which could be important if valproic acid is withdrawn.
- ↑ Farmacotherapeutisch Kompas; Toxicologie (dutch)
↑ 2.02.12.2 Farmacotherapeutisch Kompas - valproinezuur (dutch)
Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content Cite error: Invalid
<ref>tag; name "ftk" defined multiple times with different content
- ↑ KNMP; Informatorium Medicamentorum 2015; Monografie "valproaat" (Dutch)
- ↑ Interactions between valproic acid and topiramate on drugs.com
- ↑ Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.